Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINDACT
ISRCTN18543567Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of docetaxel, capecitabine, epirubicin, doxorubicin, cyclophosphamide and 4 more in breast cancer (4 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Distant metastasis-free survival and Disease-free survival. Started Mar 2007; status: completed.
02
Drugs
docetaxelcapecitabineepirubicindoxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN18543567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18543567.